Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
Leishmaniasis is a zoonosis caused by a protozoan of the Leishmania genus. First-line treatment for all forms is currently represented by the use of antimony derivatives, although toxic effects and the number of resistant strains in both immunocompromised and immunocompetent patients is increasing. Liposomal amphotericin B (L-AMB) is less toxic, more effective, and better tolerated, especially in human immunodeficiency virus-negative immunocompromised patients. We present 2 cases of transplanted patients affected by visceral leishmaniasis treated successfully with L-AMB.
Vigna
E
E
Unità Operativa Complessa di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
De Vivo
A
A
Gentile
M
M
Morelli
R
R
Lucia
E
E
Mazzone
C
C
Recchia
A G
AG
Vianelli
N
N
Morabito
F
F
D000666:Amphotericin B / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000981:Antiprotozoal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B